Kyverna Therapeutics (KYTX) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
19 Nov, 2026Strategy and platform
Miv-cel is designed for potency and improved safety; more than 100 patients treated, with durable drug-free remissions and a manageable, tolerable safety profile reported.
The construct is a fully humanized autologous CD19 CAR-T with a CD28 co-stimulatory domain and modified hinge and transmembrane regions; translational findings include CNS penetration and immune-cell changes consistent with an immune reset.
Dual-source manufacturing uses ElevateBio and Minaris Advanced Therapies; ElevateBio is the key commercial source, with a reported manufacturing success rate above 98%.
Cash runway extends well into 2028, supporting planned development and commercial milestones.
Stiff person syndrome
The first BLA for stiff person syndrome and the first BLA for an autoimmune cell therapy worldwide was filed; with RMAT designation, priority review is being sought, with FDA acceptance and a planned PDUFA date update expected in 2027.
A commercial launch is planned for 2027; launch preparation is underway, with 10 academic centers targeted as initial focal sites.
Timed 25-foot walk improved 46% at week 16 versus a 20% clinically meaningful threshold, and 49% at week 52; both results were described as highly statistically significant.
Two-thirds of patients who used a walking aid at baseline no longer needed one by week 16; this improvement continued through week 52. No high-grade CRS or ICANS, or reported IEC-HS, was reported; three treatment-related serious AEs resolved during the study.
The U.S. population includes 6,000 diagnosed patients, with 2,000–2,500 refractory to IVIG and other immunosuppressants; the targeted launch population was described as a multi-billion-dollar opportunity.
Generalized myasthenia gravis
Phase II results showed week-24 reductions of 8.3 in MG-ADL and 11.7 in QMG, with durable improvements extending to one year and beyond; meaningful clinical impact across key endpoints was reported in all patients.
A randomized, controlled pivotal Phase III study versus standard of care is enrolling; enrollment is expected to finish in mid-2027.
No high-grade CRS or ICANS, or reported IEC-HS, was observed in the study population; no severe adverse events of any grade were reported.
Latest events from Kyverna Therapeutics
- SPS BLA complete; miv-cel launch preparations advance as runway extends into 2028.KYTX
Q3 2026 - Miv-cel offers durable remission and strong safety in SPS, with expansion into gMG and PMS planned.KYTX
Investor presentation - Miv-cel delivers durable, drug-free remissions and strong safety in SPS and gMG at one year.KYTX
Study update - Miv-cel shows transformative results in SPS and gMG, with regulatory and commercial milestones ahead.KYTX
H.C. Wainwright 28th Annual Global Investment Conference - Transformative cell therapy shows strong efficacy and safety, targeting near-term approval and launch.KYTX
Morgan Stanley 24th Annual Global Healthcare Conference - Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027.KYTX
Wells Fargo 21st Annual Healthcare Conference - Miv-cel achieved durable, drug-free remission in SPS and gMG with strong safety and commercial outlook.KYTX
Corporate presentation - Q2 2026 net loss narrowed to $38.3M as miv-cel advanced with FDA RMAT and strong cash reserves.KYTX
Q2 2026 - KYV-101 demonstrates transformative efficacy in autoimmune diseases, with pivotal data expected in 2026.KYTX
Jefferies London Healthcare Conference 2025